From Wikipedia, the free encyclopedia
Reslizumab is a humanized monoclonal antibody intended for the treatment of eosinophil-meditated inflammations of the airways, skin and gastrointestinal tract. The drug is undergoing phase II/III clinical trials.
- ^ Walsh, GM (2009). "Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions". Current opinion in molecular therapeutics 11 (3): 329–36. PMID 19479666.
- ^ McIvor, RA (2015). "Emerging therapeutic options for the treatment of patients with symptomatic asthma". Annals of Allergy, Asthma & Immunology: 1–7. doi:10.1016/j.anai.2015.07.011. PMID 26254973.